Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis
- PMID: 35998555
- DOI: 10.1016/j.jdiacomp.2022.108285
Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ronald Goldenberg reports a relationship with Astra Zeneca that includes: consulting or advisory, funding grants, and speaking and lecture fees. Ronald Goldenberg reports a relationship with Eli Lilly that includes: consulting or advisory, funding grants, and speaking and lecture fees. Ronald Goldenberg reports a relationship with Novo Nordisk Inc. that includes: consulting or advisory, funding grants, and speaking and lecture fees. Ronald Goldenberg reports a relationship with Sanofi that includes: consulting or advisory, funding grants, and speaking and lecture fees.
Comment on
-
Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis.J Diabetes Complications. 2022 Aug;36(8):108255. doi: 10.1016/j.jdiacomp.2022.108255. Epub 2022 Jul 5. J Diabetes Complications. 2022. PMID: 35817678
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
